UK markets closed

DBV Technologies S.A. (DBV.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
1.33100.0000 (0.00%)
At close: 05:35PM CET
Full screen
Previous close1.3310
Open1.3440
BidN/A x N/A
AskN/A x N/A
Day's range1.3130 - 1.3440
52-week range1.0950 - 4.3000
Volume32,979
Avg. volume121,508
Market cap128.054M
Beta (5Y monthly)0.80
PE ratio (TTM)N/A
EPS (TTM)-0.7000
Earnings date07 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.09
  • Insider Monkey

    DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript

    DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript March 7, 2024 DBV Technologies S.A. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Apologies for the late start of our conference. Welcome to the DBV Full Year 2023 Financial Results […]

  • Globe Newswire

    DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

    Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K wi

  • Globe Newswire

    DBV Technologies Reports Full Year 2023 Financial Results and Business Update

    Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old)Strengthened executive leadership team in preparation for BLA submissionReported cash and cash equivalents of $141 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical compa